NCT03768219View on ClinicalTrials.gov

Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

PHASE1TerminatedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
PsoriasisUlcerative Colitis
Interventions
BIOLOGICAL

APVO210

APVO210

BIOLOGICAL

Placebo

Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
lead

Aptevo Therapeutics

INDUSTRY